CRISPR-Cas9-generated mouse model of neurofibromatosis type 1

Taegun Park, Sunghyeok Ye, Sang Kyu Shin, Kyoungmi Kim, Junho K. Hur, Junseok W. Hur

Research output: Contribution to journalArticlepeer-review


Background: To date, no experiments have been conducted to generate a neurofibromatosis type 1 (NF1) mouse model using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (CRISPR-Cas9) embryo editing system. Objective: This study was to deliver ribonucleoprotein (RnP) via electroporation in various formats and delivery methods of the CRISPR-Cas9 system for genetic modification of mouse embryonic fibroblast NIH3T3 cells and embryos. The insertion–deletion (indel) efficacy and pattern of NF1 were analyzed using next-generation sequencing (NGS). Results: We established four candidate single-guide RNAs (sgRNAs) and transfected them with Streptococcus pyogenes Cas9 (SpCas9) protein (RnP) via electroporation into NIH3T3 cells to analyze the indel efficacy and pattern of NF1. Two of the four candidates with a 50% indel efficacy were selected for embryo editing; however, without an appropriate sgRNA concentration, biallelic mutants were generated in 60–80% of the cases. Thus, by finding an appropriate concentration for RnP, it was possible to increase the rate of monoallelic mutant generation. Finally, we successfully produced an NF1 heterozygote mouse model, and the mutant sequence was confirmed using NGS. Conclusion: Our study showed that the CRISPR-Cas9 embryo editing method is an efficient tool for creating NF1 heterozygous (NF1+/−) animal model.

Original languageEnglish
Pages (from-to)277-282
Number of pages6
JournalMolecular and Cellular Toxicology
Issue number2
Publication statusPublished - 2023 Apr

Bibliographical note

Funding Information:
We would like to thank Editage ( ) for the English language editing. This study was supported by grants from the Basic Science Research Program through the National Research Foundation (NRF) funded by the Korean Ministry of Education, Science, and Technology (KR) [NRF-2017R1D1A1B03035760, NRF-2019R1C1C1010602] to JWH. This study was also supported by grants from the Korea Medical Device Development Fund (KR) [KMDF_PR_20210526_0003] to JWH and SY.

Publisher Copyright:
© 2022, The Author(s) under exclusive licence to The Korean Society of Toxicogenomics and Toxicoproteomics.


  • CRISPR-Cas9
  • Embryo editing
  • Gene editing
  • Mouse model
  • NF1
  • Neurofibromatosis type 1

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis


Dive into the research topics of 'CRISPR-Cas9-generated mouse model of neurofibromatosis type 1'. Together they form a unique fingerprint.

Cite this